1 |
NCT03007030 |
Recruiting |
Trial of Adcetris in CD30+ Malignant Mesothelioma |
- Lung Diseases Due to External Agents
- Mesothelioma
|
- Drug: Brentuximab Vedotin
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Seattle Genetics, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Disease Control Rate (DCR) in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
- Time to Progression in Pre-Treated Participants with Unresectable Malignant Pleural Mesothelioma (MPM) Treated with Brentuximab Vedotin
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03007030 |
2016-0514 NCI-2017-00069 |
|
April 5, 2017 |
April 2022 |
April 2023 |
December 30, 2016 |
March 14, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
2 |
NCT03075527 |
Recruiting |
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma |
|
- Drug: Tremelimumab
- Drug: Durvalumab
|
Interventional |
Phase 2 |
- Dana-Farber Cancer Institute
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Overall Survival
- Progression Free Survival
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT03075527 |
16-549 |
|
April 10, 2017 |
September 30, 2020 |
September 30, 2024 |
March 9, 2017 |
January 19, 2018 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
|
3 |
NCT02611037 |
Recruiting |
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
- Mesothelioma
|
- Drug: Cisplatin
- Drug: Methotrexate
- Drug: Gemcitabine
- Other: Lung Cancer Symptom Scale for Mesothelioma Questionnaire
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Overall Survival (OS)
- Progression Free Survival (PFS)
- (and 2 more...)
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT02611037 |
MCC-18094 |
|
January 4, 2016 |
December 2018 |
December 2019 |
November 20, 2015 |
December 14, 2017 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
4 |
NCT03436732 |
Recruiting |
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma |
|
- Drug: LMB-100
- Drug: SEL-110
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- safety and tolerability
- maximum tolerated dose
- descriptive statistics of pharmacokinetic parameters including half life, clearnace, AUC, volume of distribution
- (and 2 more...)
|
20 |
All |
18 Years to 99 Years (Adult, Senior) |
NCT03436732 |
180057 18-C-0057 |
|
February 28, 2018 |
November 29, 2019 |
November 30, 2020 |
February 19, 2018 |
March 22, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
5 |
NCT02899195 |
Recruiting |
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma |
- Mesothelioma
- Pleural Mesothelioma
|
- Drug: Concurrent Durvalumab
- Drug: Maintenance Durvalumab
|
Interventional |
Phase 2 |
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.03
- Progression-Free Survival (PFS)
- (and 2 more...)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT02899195 |
PrE0505 ESR-15-10792 |
PrE0505 |
June 13, 2017 |
August 2020 |
December 2020 |
September 14, 2016 |
April 11, 2018 |
|
- University San Diego Moores Cancer Center
La Jolla, California, United States - Ronald Reagan UCLA Medical Center
Los Angeles, California, United States - Stanford Cancer Institute
Stanford, California, United States - (and 16 more...)
|
6 |
NCT02139904 |
Recruiting |
Vinorelbine in Mesothelioma |
|
- Drug: Vinorelbine
- Other: Active Symptom Control
|
Interventional |
Phase 2 |
- Wales Cancer Trials Unit
- Pierre Fabre Laboratories
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival
- Progression Free Survival
- Number of serious adverse events reported
- BRCA1 status in blood and tumour samples
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02139904 |
UNOLE 0329 |
VIM |
March 1, 2016 |
March 1, 2018 |
December 1, 2018 |
May 15, 2014 |
April 11, 2017 |
|
- Wales Cancer Trials Unit
Cardiff, United Kingdom
|
7 |
NCT02991482 |
Recruiting |
PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma |
- Pleural Mesothelioma Malignant Advanced
|
- Drug: Pembrolizumab
- Drug: Gemcitabine
- Drug: Vinorelbine
|
Interventional |
Phase 3 |
- European Thoracic Oncology Platform
- Merck Sharp & Dohme Corp.
- Frontier Science Foundation, Hellas
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) in patients with advanced pre-treated malignant mesothelioma.
- Objective response.
- Overall survival.
- (and 3 more...)
|
142 |
All |
18 Years and older (Adult, Senior) |
NCT02991482 |
ETOP 9-15 2016-002062-31 3475-594 |
PROMISE-meso |
September 12, 2017 |
December 2020 |
December 2020 |
December 13, 2016 |
February 20, 2018 |
|
- ICO Hospitalet
Barcelona, Spain - Hospital Teresa Herrera
La Coruña, Spain - Hospital Clínico Universitario de Valladolid
Valladolid, Spain - (and 12 more...)
|
8 |
NCT02838745 |
Recruiting |
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas |
|
- Drug: Pemetrexed
- Drug: Cisplatin
|
Interventional |
Phase 1 |
- Baylor College of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Safety Maximum Tolerated Dose of HIOC with cisplatin and pemetrexed for Malignant Pleural Mesothelioma.
|
36 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02838745 |
H-36460 |
|
September 2016 |
July 2018 |
August 2018 |
July 20, 2016 |
October 27, 2017 |
|
- Baylor St Lukes
Houston, Texas, United States
|
9 |
NCT02707666 |
Recruiting |
A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma |
|
- Drug: Pembrolizumab
- Drug: Cisplatin and Pemetrexed
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Gamma-Interferon Gene Expression profile (GEP) response rate defined as an increase beyond the median value of the sum of individual genes
- Number of participants with adverse events as measured by CTCAEv4.0
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02707666 |
IRB15-1149 |
|
February 2016 |
March 2018 |
September 2018 |
March 14, 2016 |
January 4, 2018 |
|
- University of Chicago
Chicago, Illinois, United States
|
10 |
NCT02385812 |
Recruiting |
Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma |
|
- Procedure: Low-dose computed tomography Annual scan x3
- Procedure: Low-dose computed tomography Baseline scan only
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Change in SF-12 quality of life score
- Change in EQ-5D and STAI
- Lung cancer detection rate
- Mesothelioma detection rate
|
200 |
All |
50 Years to 80 Years (Adult, Senior) |
NCT02385812 |
10007822 |
|
April 2015 |
December 2019 |
December 2019 |
March 11, 2015 |
October 6, 2017 |
|
- University of Calgary
Calgary, Alberta, Canada - University of Alberta
Edmonton, Alberta, Canada
|
11 |
NCT02761863 |
Not yet recruiting |
Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Other: CD 74, VEGF detection
|
Observational |
|
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- CD 74 and VEGF detection effect on response to treatment
|
100 |
All |
19 Years to 70 Years (Adult, Senior) |
NCT02761863 |
CURE001 |
|
July 30, 2019 |
January 30, 2020 |
July 30, 2021 |
May 4, 2016 |
February 23, 2018 |
|
|
12 |
NCT03213301 |
Recruiting |
Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. |
- Malignant Pleural Mesothelioma, Advanced
|
|
Interventional |
Phase 2 |
- Swiss Group for Clinical Cancer Research
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS) at 12 weeks
- Progression-free survival (PFS)
- Objective response (OR)
- (and 3 more...)
|
43 |
All |
18 Years and older (Adult, Senior) |
NCT03213301 |
SAKK 17/16 2017-001016-11 |
|
September 28, 2017 |
July 1, 2019 |
March 1, 2022 |
July 11, 2017 |
February 1, 2018 |
|
- Kantonsspital Baden
Baden, Switzerland - IOSI Ospedale Regionale di Bellinzona e Valli
Bellinzona, Switzerland - Kantonsspital Graubuenden
Chur, Switzerland - (and 3 more...)
|
13 |
NCT02519049 |
Recruiting |
11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) |
|
|
Observational |
|
- Istituto Clinico Humanitas
|
Other |
- Time Perspective: Prospective
|
- Variation of SUVmax (Maximal Standardized Uptake Value) in patients undergoing talc pleurodesis
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02519049 |
1287 |
|
September 2014 |
September 2017 |
November 2017 |
August 10, 2015 |
November 21, 2016 |
|
- Istituto Clinico Humanitas
Rozzano, Milano, Italy
|
14 |
NCT02194231 |
Recruiting |
ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM) |
- Malignant Pleural Mesothelioma
|
|
Interventional |
Phase 2 |
- Mario Negri Institute for Pharmacological Research
- PharmaMar
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival - PFS12w
- Progression Free Survival (PFS)
- Overall survival (OS)
- (and 8 more...)
|
141 |
All |
18 Years and older (Adult, Senior) |
NCT02194231 |
IRFMN-MPM-6077 2011-006330-16 |
ATREUS |
July 2013 |
November 2018 |
November 2018 |
July 18, 2014 |
March 29, 2018 |
|
- Azienda ospedaliera ss. Antonio e Biagio e Cesare Arrigo
Alessandria, AL, Italy - Cliniche Humanitas Gavazzeni
Bergamo, BG, Italy - Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
Bologna, Bo, Italy - (and 6 more...)
|
15 |
NCT03269227 |
Recruiting |
Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Radiation: Accelerated hypofractionation with Tomotherapy
|
Interventional |
Not Applicable |
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
- Overall survival (OS)
- Disease control rate (DCR)
- time to progessione (TTP)
|
30 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT03269227 |
IRST163.01 |
MesoRT |
August 14, 2017 |
July 2020 |
July 2020 |
August 31, 2017 |
September 11, 2017 |
|
- SC Radiotherapy
Meldola, Italy
|
16 |
NCT03063450 |
Recruiting |
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma |
|
- Drug: Nivolumab
- Other: Placebo
|
Interventional |
Phase 3 |
- University of Southampton
- University of Leicester
- University of Sheffield
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Overall survival
- modified RECIST or RECIST 1.1 - progression free survival
- modified RECIST or RECIST 1.1 - overall response rate
- (and 3 more...)
|
336 |
All |
18 Years and older (Adult, Senior) |
NCT03063450 |
22864 2016-003111-35 CA290841 A21400 |
CONFIRM |
March 28, 2017 |
June 2021 |
July 2021 |
February 24, 2017 |
February 27, 2018 |
|
- Aberdeen Royal Infirmary
Aberdeen, United Kingdom - Royal Bournemouth Hospital
Bournemouth, United Kingdom - Velindre Cancer Centre
Cardiff, United Kingdom - (and 8 more...)
|
17 |
NCT02798536 |
Recruiting |
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma |
|
- Drug: LMB-100
- Drug: nab-paclitaxel
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dose of LMB100 +nab-paclitaxel
- maximum tolerated dose of LMB-100
- proportion of patients at MTD with paartial or complete response per RECIST
- (and 5 more...)
|
34 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02798536 |
160127 16-C-0127 |
|
June 10, 2016 |
August 6, 2019 |
August 5, 2020 |
June 14, 2016 |
April 5, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
18 |
NCT02662504 |
Recruiting |
Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Device: photodynamic therapy (PDT)
- Procedure: thoracic surgery Pleurectomy / extended Decortication
- Drug: Adjuvant chemotherapy
|
Interventional |
Phase 2 |
- University Hospital, Lille
- Institut National de la Santé Et de la Recherche Médicale, France
- University of Pennsylvania
- Région Nord-Pas de Calais, France
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients having the full multimodal treatment without unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0
- Number of responders or stable patients after surgery
- Progression-free survival (PFS)
- Quality of life assessed by a specific questionnaire MPM (HCCA EORTC-30)
|
6 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02662504 |
2014_01 2015-001554-15 |
MesoPDT |
January 2016 |
January 2019 |
January 2019 |
January 25, 2016 |
August 23, 2017 |
|
- CHRU de Lille Hôpital Calmette
Lille, France
|
19 |
NCT02784171 |
Recruiting |
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma |
|
- Drug: Cisplatin
- Drug: Pemetrexed
- Drug: Pembrolizumab
|
Interventional |
Phase 2 |
- Canadian Cancer Trials Group
- National Cancer Institute, Naples
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival measured as time from randomization to first observation of objective disease relapse or progression
- Number and severity of adverse events
- Overall Survival
- (and 2 more...)
|
126 |
All |
18 Years and older (Adult, Senior) |
NCT02784171 |
I227 2016-002286-60 |
|
October 7, 2016 |
May 2019 |
December 2019 |
May 26, 2016 |
April 11, 2018 |
|
- Tom Baker Cancer Centre
Calgary, Alberta, Canada - Cross Cancer Institute
Edmonton, Alberta, Canada - BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada - (and 24 more...)
|
20 |
NCT02464904 |
Recruiting |
Intrapleural Cryotherapy for Malignant Pleural Mesothelioma |
|
- Device: Cryotherapy
- Other: Control
|
Interventional |
Not Applicable |
- Mayo Clinic
- CSA Medical, Inc.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events
- Mean Number of Tumor Infiltrating Immune Cells as Measured by Immunohistochemistry on Participant Tissue Samples
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02464904 |
14-008715 |
|
July 2015 |
December 2018 |
December 2018 |
June 8, 2015 |
January 9, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
21 |
NCT02592551 |
Recruiting |
MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma |
|
- Drug: MEDI4736
- Drug: Tremelimumab
- Other: Untreated arm (control)
|
Interventional |
Phase 2 |
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Intratumoral ratio of CD8 T cells to regulatory T cells (CD8/Treg). [Ratio]
- The percentage of inducible T-cell co-stimulator (ICOS) + CD4 T cells.
- The tumor expression programmed death-ligand 1 (PD-L1). [Semi-quantitative assessment: 0, 1+, 2+, 3+, 4+]
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02592551 |
H-36952 |
|
May 2016 |
May 2018 |
June 2018 |
October 30, 2015 |
January 4, 2018 |
|
- Baylor St Lukes
Houston, Texas, United States
|
22 |
NCT02899299 |
Recruiting |
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients |
|
- Biological: Nivolumab
- Biological: Ipilimumab
- Drug: Pemetrexed
- (and 2 more...)
|
Interventional |
Phase 3 |
- Bristol-Myers Squibb
- Ono Pharmaceutical Co. Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Progression Free Survival (PFS)
- Objective Response Rate (ORR)
- (and 2 more...)
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT02899299 |
CA209-743 2016-001859-43 |
CheckMate743 |
October 25, 2016 |
October 4, 2020 |
September 28, 2021 |
September 14, 2016 |
April 10, 2018 |
|
- Ucsf
San Francisco, California, United States - Yale University
New Haven, Connecticut, United States - Local Institution
Fort Myers, Florida, United States - (and 126 more...)
|
23 |
NCT03177668 |
Recruiting |
Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
|
Interventional |
Phase 1 Phase 2 |
- Kissei Pharmaceutical Co., Ltd.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Status of onset of Dose Limiting Toxicity (DLT)
- Disease Control Rate (DCR)
- Progression Free Survival (PFS)
- (and 4 more...)
|
48 |
All |
20 Years and older (Adult, Senior) |
NCT03177668 |
YS1101 |
|
June 2017 |
December 2020 |
December 2020 |
June 6, 2017 |
June 6, 2017 |
|
- Research Site
Tokyo and Other Japanese Cities, Japan
|
24 |
NCT03502746 |
Not yet recruiting New |
Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma |
|
- Drug: Nivolumab
- Drug: Ramucirumab
|
Interventional |
Phase 2 |
- Arkadiusz Z. Dudek, MD
- HealthPartners Institute Regions Cancer Care Center
- Eli Lilly and Company
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response Rate
- Adverse event assessment
- Progression-free survival
- Overall survival
|
35 |
All |
18 Years and older (Adult, Senior) |
NCT03502746 |
HCRN-LUN15-299 |
|
May 2018 |
March 2020 |
March 2021 |
April 19, 2018 |
April 19, 2018 |
|
- HealthPartners Institute Regions Cancer Care Center
Minneapolis, Minnesota, United States
|
25 |
NCT02649829 |
Recruiting |
Autologous Dendritic Cell Vaccination in Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Biological: dendritic cell vaccination plus chemotherapy
|
Interventional |
Phase 1 Phase 2 |
- University Hospital, Antwerp
- Kom Op Tegen Kanker
- stichting tegen kanker
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of MPM patients with feasible and safe DC vaccine production
- Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame
- Objective clinical responses by tumor evaluation (clinical efficacy)
- (and 3 more...)
|
20 |
All |
18 Years and older (Adult, Senior) |
NCT02649829 |
CCRG13-002 |
MESODEC |
August 1, 2017 |
October 2020 |
November 2021 |
January 8, 2016 |
December 11, 2017 |
|
- Antwerp University Hospital
Edegem, Antwerp, Belgium - AZ Middelares
Ghent, Belgium - AZ Nikolaas
Sint-Niklaas, Belgium
|
26 |
NCT02863055 |
Not yet recruiting |
Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Drug: Nintedanib
- Drug: Placebo
|
Interventional |
Phase 2 |
- European Organisation for Research and Treatment of Cancer - EORTC
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Progression-free survival
- Overall survival
- Overall Response Rate
|
116 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT02863055 |
EORTC-08112 |
NEMO |
December 2017 |
December 2019 |
June 2020 |
August 11, 2016 |
November 13, 2017 |
|
|
27 |
NCT02414945 |
Recruiting |
Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma |
|
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Biological: Autologous tumor infiltrating lymphocytes (TILs)
- Biological: Interleukin-2
|
Interventional |
Phase 1 Phase 2 |
- University Health Network, Toronto
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Total number of adverse events for each event reported and the severity and attribution to study therapy of each event
- Percentage of patients with a clinical response to the study treatment
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02414945 |
TILs-003-Meso |
|
June 2015 |
June 2025 |
November 2025 |
April 13, 2015 |
February 14, 2018 |
|
- Princess Margaret Cancer Centre
Toronto, Ontario, Canada
|
28 |
NCT02040272 |
Recruiting |
MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma |
|
- Procedure: (Extended) pleurectomy decortication
|
Interventional |
Not Applicable |
- Royal Brompton & Harefield NHS Foundation Trust
- Cancer Research UK
- Papworth Hospital NHS Foundation Trust
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ability to randomise 50 patients
- Survival from the time point of randomisation
- Quality of life as assessed using QLQ 30 and LC-13 scales
|
50 |
All |
Child, Adult, Senior |
NCT02040272 |
MARS2 |
MARS2 |
May 2015 |
May 2017 |
June 2017 |
January 20, 2014 |
May 12, 2017 |
|
- Burton Hospitals NHS Foundation Trust
Burton, United Kingdom - Papworth
Cambridge, United Kingdom - Cardiff
Cardiff, United Kingdom - (and 12 more...)
|
29 |
NCT03412357 |
Recruiting |
MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma. |
- Malignant Pleural Mesothelioma
- Trapped Lung
|
- Procedure: pleurectomy/decortication
- Procedure: indwelling pleural catheter
|
Interventional |
Not Applicable |
- Papworth Hospital NHS Foundation Trust
- National Institute for Health Research, United Kingdom
- London School of Hygiene and Tropical Medicine
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To measure the standard deviation of Visual Analogue Scale scores for breathlessness
- To measure the standard deviation of Visual Analogue Scale scores for chest pain
- Quality of Life measured using the EQ-5D-5L
- (and 7 more...)
|
38 |
All |
18 Years and older (Adult, Senior) |
NCT03412357 |
PO2128 |
MesoTRAP |
August 10, 2017 |
December 1, 2018 |
December 1, 2019 |
January 26, 2018 |
January 26, 2018 |
|
- Blackpool Teaching Hospitals NHS Foundation Trust
Blackpool, United Kingdom - North Bristol NHS Trust
Bristol, United Kingdom - Papworth Hospital NHS Foundation Trust
Cambridge, United Kingdom - (and 8 more...)
|
30 |
NCT00715611 |
Recruiting |
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma |
|
- Procedure: Pleurectomy/Decortication
- Drug: pemetrexed and cisplatin or carboplatin
- Radiation: Intensity Modulated Radiation Therapy
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- M.D. Anderson Cancer Center
- Princess Margaret Hospital, Canada
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients ≥ grade 3 pneumonitis
|
81 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT00715611 |
08-053 |
|
July 11, 2008 |
July 2018 |
July 2018 |
July 15, 2008 |
January 8, 2018 |
|
- Brigham and Women's Hospital
Boston, Massachusetts, United States - Mayo Clinic Cancer Center
Rochester, Minnesota, United States - Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - (and 7 more...)
|
31 |
NCT02672033 |
Recruiting |
Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma |
- Pleural Epithelioid Mesothelioma
- Pleural Malignant Mesothelioma
|
- Radiation: Hypofractionated Radiation Therapy
- Radiation: Intensity-Modulated Radiation Therapy
- Other: Laboratory Biomarker Analysis
- Procedure: Therapeutic Conventional Surgery
|
Interventional |
Not Applicable |
- Jonsson Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ability to accrue sufficient patients to draw conclusions about endpoints in a timely and expedient manner
- Incidence of acute and subacute toxicity defined as grade 4 or 5 adverse events as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Incidence of chronic toxicity as assessed by the NCI CTCAE version 4.0
- (and 4 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02672033 |
15-000487 NCI-2015-01736 JCCCID552 P30CA016042 |
|
September 1, 2015 |
September 1, 2018 |
September 1, 2019 |
February 3, 2016 |
August 28, 2017 |
|
- UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
|
32 |
NCT03399552 |
Recruiting |
Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma |
- Malignant Mesothelioma (MPM)
|
- Drug: Avelumab
- Radiation: Stereotactic Body Radiation Therapy
|
Interventional |
Phase 1 Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Pfizer
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT03399552 |
17-358 |
|
December 20, 2017 |
December 2020 |
December 2020 |
January 16, 2018 |
January 29, 2018 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
33 |
NCT01358084 |
Recruiting |
Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced Malignant Pleural Mesothelioma |
- Advanced Malignant Pleural Mesothelioma
|
- Drug: NGR-hTNF
- Drug: Placebo
- Other: Best Supportive Care
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS)
- Overall survival (OS)
- Tumor response
- (and 2 more...)
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01358084 |
NGR019 2010-023614-31 |
NGR019 |
March 2011 |
December 2016 |
December 2017 |
May 23, 2011 |
May 30, 2016 |
|
- Zentralklinik Bad Berka GmbH
Bad Berka, Thuringia, Germany - Asklepios Fachkliniken München-Gauting
München-Gauting, Germany - Ospedale Santo Spirito
Casale Monferrato, Alessandria, Italy - (and 12 more...)
|
34 |
NCT02568449 |
Recruiting |
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent |
- Recurrent Pleural Malignant Mesothelioma
- Stage IV Pleural Mesothelioma
|
|
Interventional |
Phase 2 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival (PFS)
- Incidence of grade 3-4 toxicity rate
- Overall survival
- Response rate (complete and partial response)
|
55 |
All |
18 Years and older (Adult, Senior) |
NCT02568449 |
2015-010 NCI-2015-01412 1506014121 P30CA022453 |
|
October 2015 |
January 1, 2018 |
January 1, 2018 |
October 5, 2015 |
March 30, 2017 |
|
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States - Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
35 |
NCT01722149 |
Recruiting |
Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Genetic: Adoptive Transfer of re-directed T cells
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
6 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01722149 |
FAPME-1 |
|
February 2015 |
December 2018 |
December 2018 |
November 6, 2012 |
January 2, 2018 |
|
- University Hospital Zurich, Division of Oncology
Zurich, ZH, Switzerland
|
36 |
NCT02709512 |
Recruiting |
Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin |
|
- Drug: ADI-PEG 20 plus Pem Cis
- Other: Placebo plus Pem Cis
|
Interventional |
Phase 2 Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Response Rate
- Progression Free Survival
|
386 |
All |
18 Years and older (Adult, Senior) |
NCT02709512 |
POLARIS2015-003 |
ATOMIC |
October 2016 |
August 2018 |
June 2019 |
March 16, 2016 |
February 22, 2018 |
|
- Mayo Clinic
Phoenix, Arizona, United States - UCLA Hematology & Oncology - Santa Monica
Los Angeles, California, United States - University of California San Francisco Helen Diller Comprehensive Cancer Center
San Francisco, California, United States - (and 9 more...)
|
37 |
NCT01644994 |
Recruiting |
Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Combination Product: intracavitary cisplatin-fibrin
|
Interventional |
Phase 1 Phase 2 |
- University of Zurich
- Swiss National Science Foundation
- Swiss Accident Insurance Fund SUVA
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events (Safety)
- Cisplatin concentration in the superficial chest wall tissue
- overall survival
- (and 8 more...)
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT01644994 |
INFLuenCe - Meso |
|
November 2012 |
August 2020 |
August 2020 |
July 19, 2012 |
August 24, 2017 |
|
- University Hospital Zurich, Division of Thoracic Surgery
Zurich, ZH, Switzerland
|
38 |
NCT03126630 |
Recruiting |
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma |
- Mesothelin Positive
- Pleural Malignant Mesothelioma
|
- Biological: Anetumab Ravtansine
- Other: Laboratory Biomarker Analysis
- Biological: Pembrolizumab
- Other: Pharmacological Study
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recommended phase 2 dose of anetumab ravtansine with combination of pembrolizumab
- Confirmed tumor response rate assessed using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria (Phase II)
- Duration of response defined as evaluable patients who achieved noted to be a partial response or complete response based Response Evaluation Criteria in Solid Tumors version 1.1 criteria
- (and 6 more...)
|
134 |
All |
18 Years and older (Adult, Senior) |
NCT03126630 |
NCI-2017-00633 MC1721 10107 UM1CA186686 |
|
February 8, 2018 |
February 2, 2020 |
February 2, 2020 |
April 24, 2017 |
March 5, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
39 |
NCT03393858 |
Recruiting |
Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma |
- Cancer
- Mesothelioma, Malignant
|
- Drug: Anti-PD-1 antibody
- Biological: DC-CIK Immunotherapy
- Device: Thermotron RF-8EX
|
Interventional |
Phase 1 Phase 2 |
- Capital Medical University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free survival of the participants(PFS)
- Overall survival of the participants(OS)
- Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
- Safety (adverse events)
|
40 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03393858 |
RF8-MM |
|
December 1, 2017 |
June 2020 |
December 2020 |
January 9, 2018 |
January 12, 2018 |
|
- Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital
Beijing, China
|
40 |
NCT03319537 |
Recruiting |
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma |
|
- Drug: pevonedistat
- Drug: Pemetrexed and cisplatin
|
Interventional |
Phase 1 Phase 2 |
- Memorial Sloan Kettering Cancer Center
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- number of patients who have a clinical benefit rate (CBR) (cohort 1)
- maximum tolerated dose (MTD) (cohort 2)
|
42 |
All |
18 Years and older (Adult, Senior) |
NCT03319537 |
17-361 |
|
October 5, 2017 |
October 2020 |
October 2020 |
October 24, 2017 |
February 14, 2018 |
|
- Memorial Sloan Kettering at Basking Ridge
Basking Ridge, New Jersey, United States - Memoral Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
41 |
NCT00188890 |
Recruiting |
Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers |
|
|
Observational |
|
- University Health Network, Toronto
|
Other |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
2000 |
All |
30 Years to 85 Years (Adult, Senior) |
NCT00188890 |
Asbestos Screening Study |
|
March 2005 |
March 2022 |
March 2022 |
September 16, 2005 |
March 26, 2018 |
|
- Princess Margaret Hospital
Toronto, Ontario, Canada
|
42 |
NCT02648763 |
Recruiting |
Staging Procedures to Diagnose Malignant Pleural Mesothelioma |
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Accuracy of surgical staging versus imaging procedures based on surgical findings.
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02648763 |
15-007647 |
|
March 14, 2016 |
December 2018 |
December 2018 |
January 7, 2016 |
January 9, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
43 |
NCT02613299 |
Recruiting |
Surgery for Mesothelioma After Radiation Therapy "SMART" for Resectable Malignant Pleural Mesothelioma |
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Survival status upon review of patient records every 6 months
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02613299 |
15-007644 |
|
November 2015 |
December 2018 |
December 2019 |
November 24, 2015 |
January 9, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
44 |
NCT02959463 |
Recruiting |
Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma |
- Malignant Pleural Mesothelioma
|
- Radiation: Hemithoracic Radiation Therapy
- Radiation: Palliative Radiation Therapy
- Drug: Pembrolizumab
|
Interventional |
Phase 1 |
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Undergone at Least 2 Cycles of Chemotherapy and Possible Lung-Sparing Surgery
- Treatment-Related Toxicity of Adding Pembrolizumab with Radiation Therapy in Participants who Have Possibly Received Prior Chemotherapy and No Surgery
- Tumor Response
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT02959463 |
2015-0856 NCI-2016-01923 |
|
May 1, 2017 |
May 2020 |
May 2021 |
November 9, 2016 |
March 21, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
45 |
NCT01503177 |
Recruiting |
Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma |
- Recurrent Malignant Mesothelioma
- Stage IA Malignant Mesothelioma
- Stage IB Malignant Mesothelioma
- (and 3 more...)
|
- Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter
- Other: laboratory biomarker analysis
- Procedure: single photon emission computed tomography
- Procedure: computed tomography
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse event (AE) profile
- Describe the safety of the intrapleural administration of MV-NIS in patients with malignant pleural mesothelioma for all cycles out to 90 days.
|
36 |
All |
18 Years and older (Adult, Senior) |
NCT01503177 |
MC1023 NCI-2011-03574 |
|
November 2011 |
January 2019 |
January 2019 |
January 2, 2012 |
August 29, 2017 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|
46 |
NCT02613312 |
Recruiting |
Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma |
- Mesothelioma
- Solitary Fibrous Tumor of the Pleura
|
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Survival status upon review of patients every 6 months
- Progression free survival as evidenced by CT scan review
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02613312 |
15-007645 |
|
March 18, 2016 |
December 2018 |
December 2018 |
November 24, 2015 |
January 9, 2018 |
|
- Mayo Clinic in Rochester
Rochester, Minnesota, United States
|
47 |
NCT01950572 |
Recruiting |
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma |
- Mesothelioma
- Thymoma
- Pancreatic Neoplasms
- (and 2 more...)
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
|
1000 |
All |
2 Years to 100 Years (Child, Adult, Senior) |
NCT01950572 |
130202 13-C-0202 |
|
September 21, 2013 |
December 31, 2030 |
December 31, 2030 |
September 25, 2013 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
48 |
NCT03228537 |
Recruiting |
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma |
- Biphasic Mesothelioma
- Epithelioid Mesothelioma
- Stage I Pleural Malignant Mesothelioma AJCC v7
- (and 4 more...)
|
- Drug: Atezolizumab
- Drug: Cisplatin
- Procedure: Extrapleural Pneumonectomy
- (and 4 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival
- Overall survival
- Modified Response Evaluation Criteria in Solid Tumors (RECIST) progression free survival
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT03228537 |
NCI-2017-01230 S1619 U10CA180888 |
|
November 3, 2017 |
June 1, 2020 |
June 1, 2020 |
July 25, 2017 |
April 13, 2018 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States - Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, United States - (and 132 more...)
|
49 |
NCT02535312 |
Recruiting |
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin |
- Advanced Malignant Solid Neoplasm
- Advanced Peritoneal Malignant Mesothelioma
- Advanced Pleural Malignant Mesothelioma
- (and 15 more...)
|
- Drug: Cisplatin
- Other: Laboratory Biomarker Analysis
- Drug: Methoxyamine
- (and 2 more...)
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (version 5.0 as of April 1, 2018) (Arm A)
- Response rate using Response Evaluation Criteria in Solid Tumors (RECIST) (Arm B)
- Pharmacokinetic (PK) parameter
- (and 3 more...)
|
58 |
All |
18 Years and older (Adult, Senior) |
NCT02535312 |
NCI-2015-00127 PHI-76 9837 UM1CA186689 UM1CA186705 UM1CA186717 ZIABC011078 |
|
August 11, 2015 |
December 31, 2018 |
|
August 28, 2015 |
April 17, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - Los Angeles County-USC Medical Center
Los Angeles, California, United States - USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States - (and 10 more...)
|
50 |
NCT02879669 |
Recruiting |
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma |
- To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy
|
- Biological: ONCOS-102
- Drug: Pemetrexed/cisplatin
- Drug: Cyclophosphamide
|
Interventional |
Phase 1 Phase 2 |
- Targovax Oy
- Theradex
- Targovax ASA
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with any (Serious and Non-Serious) Adverse Event measured to assess safety and tolerability
- To determine and compare tumour-specific immunological activation in the peripheral blood in the experimental group and the control group. Number of patients in the respective arms with induction of Tumor specific CD8+ T Cells in PBMC
- To determine and compare immunological activation in tumour mass in the experimental group and the control Group. Number of patients in the respective arms with infiltration of CD8+ T Cells into tumours
- (and 5 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT02879669 |
ONCOS C719 2015-005143-13 |
|
June 2016 |
December 2018 |
|
August 26, 2016 |
October 25, 2017 |
|
- Hospital Universitario Quirón
Barcelona, Spain - Hospital Universitari de Girona Doctor Josep Trueta - Institut Català d'Oncologia
Girona, Spain - Hospital 12 de octubre
Madrid, Spain - Hospital Universitario HM Sanchinarro
Madrid, Spain
|